Loading...
•
Dec 31, 2025
Arrowhead Pharmaceuticals Q1 2026 Earnings Report
Arrowhead Pharmaceuticals reported strong revenue growth and returned to profitability in the quarter.
Key Takeaways
Arrowhead Pharmaceuticals delivered a profitable fiscal Q1 2026 driven by a significant increase in revenue, reflecting milestone and collaboration-related income, while maintaining substantial cash resources to support pipeline advancement.
Revenue increased sharply year over year to $264.0 million
Company generated positive operating income after prior-year losses
Net income turned positive at $30.8 million
Balance sheet remained strong with over $900 million in total cash resources
Forward Guidance
Management indicated confidence in continued execution across its commercial launch and clinical pipeline through fiscal 2026.
Positive Outlook
- Successful launch of first commercial product
- Multiple regulatory approvals across geographies
- Strong liquidity to fund R&D programs
- Broad and advancing RNAi pipeline
- Strategic partnerships providing milestone potential
Challenges Ahead
- Ongoing high R&D expense requirements
- Dependence on regulatory outcomes
- Commercial execution risk for new product launch
- Potential variability in milestone timing
- Biotechnology market volatility
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...